Veoza (fezolinetant) - Risk of drug-induced liver injury and new recommendations on monitoring of liver function before and during treatment
13/01/2025
Medicines for human use
Direct healthcare professional communication (DHPC)
Important Safety Information from Astellas Pharma Europe regarding Veoza (fezolinetant): Risk of drug-induced liver injury and new recommendations on monitoring of liver function before and during treatment